New Frontiers Science Park

Last updated

New Frontiers Science Park
PHE Harlow
Glaxo Smith Kline research unit, Harlow - geograph.org.uk - 1444766.jpg
Seen in August 2009
Essex UK location map.svg
Red pog.svg
Location within Essex
Former namesGSK Harlow
General information
TypeScience park, former research centre
AddressPinnacles Industrial Estate, Harlow, Essex, CM19 5AD
Coordinates 51°45′57″N0°04′09″E / 51.7659°N 0.0693°E / 51.7659; 0.0693
Elevation65 m (213 ft)
Construction startedSeptember 1994
CompletedApril 1997
Inaugurated28 April 1997
Cost£250m
Client SmithKline Beecham Pharmaceuticals
Owner Public Health England
Dimensions
Other dimensions18.53 hectares
Design and construction
Main contractorLMK Joint Venture (Laing)

The New Frontiers Science Park is a science park in Essex, on a redeveloped research site of GlaxoSmithKline (GSK).

Contents

History

Beecham Research Laboratories opened a 4 acre site around October 1969, with 80 staff. [1] By 1988 there were 430 staff. In 1971 Beecham Group tried to take over Glaxo; it became SmithKline Beecham in 1989. Beecham bought the former Ohmeda site in Harlow from BOC in November 1988. [2] New buildings were added by SmithKline Beecham in 1990. The main Beecham headquarters, Beecham House, was in Brentford, Middlesex; the current GSK headquarters is the former Beecham headquarters.

Beecham built a penicillin plant in Worthing, West Sussex, in the early 1960s. Beecham had another large research site at Betchworth, Surrey. [3] Merck & Co. built its nearby Neuroscience Research Centre in 1984.

Construction

Outline planning application was discussed in a Harlow district council meeting on Tuesday 8 June 1993, with twelve animal rights protesters at the meeting. The site would be 878,000 square feet. Two Essex Police officers were asked to attend the meeting, as it was a known 'sensitive issue'. At first, during the meeting, the animal rights individuals were even-tempered, and held no obvious open hostility to the district councillors present; or so it may have seemed. But when the Labour district councillors voted to allow the development to be built, the animal rights individuals soon lost their temper, and vindictively promised 'huge protests' against the proposed development, generously describing SmithKline Beecham as 'bloody murderers'. [4]

Full construction plans were submitted on Tuesday 19 July 1994, [5] with final planning permission being given in early September 1994, with construction starting soon afterwards.

On Thursday 16 March 1995, 43 year old carpenter Dennis Gough, of Enfield, fell 30 feet off scaffolding. He was taken to the Princess Alexandra Hospital, but died in the early hours of the next day. [6] [7]

Construction would be finished by November 1996. Further work would take around one year, to make the interior a sterile environment. [8] The site was built by LMK Joint Venture (Laing Management and Morrison–Knudsen). The same joint venture LMK would later build the Pfizer Campus in Kent. [9]

Opening

George Poste was the chief science and technology officer of the company. There were two buildings - Science Complex One, to the north, and Pharmaceutical Technologies, to the south. [10] Th inauguration took place on Monday 28 April 1997, with around 500 guests, including Martin Bangemann from the European Commission. [11]

SmithKline Beecham

Smith, Kline & French had been headquartered in Welwyn Garden City; it merged with Beecham Group in 1989. [12] Smith Kline & French Research had a research site at Welwyn Garden City and another at The Frythe in rural Hertfordshire in the south of Welwyn; in the early 1980s all research was moved out of Welwyn Garden City to The Frythe.

The site was built by SmithKline Beecham, which became GSK in December 2000 when it merged with Glaxo Wellcome. The site was the UK headquarters of SmithKline Beecham; Glaxo had a takeover of Wellcome in 1995. SmithKline Beecham employed 47,000 staff around the world, with 8,200 in the UK. Jan Leschly (a Danish tennis player) was chief executive of SmithKline Beecham from 1994 to 2000. SmithKline Beecham exported £1.2bn of products. In 1998, SmithKline Beecham spent £910m on research, with £330m of that in the UK.

Beecham Pharmaceuticals previously had its Medicinal Research Centre on the site., [13] where it worked on hypertension and gastrointestinal disease.

The site was visited by the Princess Royal on the afternoon of 3 February 2000, [14] following on in the morning from attending a meeting about the new Basic Skills Agency.

GSK

SmithKline Beecham became GSK. After the merger, a possibility was that the Harlow site would close or Glaxo Wellcome's Glaxo Research Campus in Stevenage would close; at the time of its construction in the early 1990s, Glaxo Stevenage was the largest single construction site in the UK. At the time of the merger, the USA was accounting for 45% of GSK's sales, with 33% in Europe, and 22% in the rest of the world. The company would be the world's largest pharmaceutical company with a market capitalisation of £114bn. GSK was the largest private sector funder of research in the UK.

Research

Working with the University of Cambridge, in 2000 a team gave mice a human gene that made the protein UCP3, that was found on the human Chromosome 11. The genetically-engineered mice never became overweight, no matter what the mice ate. [15]

2012 Summer Olympics

The site was the Official Laboratory Services Provider for the 2012 Summer Olympics; every medallist and 50% of competitors were tested by GSK there. 150 scientists from King's College London and the World Anti-Doping Agency would be there, to take around 6,000 samples. 240 prohibited substances would be tested for, with about 400 samples per day. By April 2017, 29 medals had been stripped from competitors in the 2012 Olympics, with 13 of these from Russia. [16]

Public Health England

Since 2010, the Health Protection Agency had wanted to move scientific staff to the GSK site in Essex. GSK had proposed to move from the site in February 2010.

Public Health England bought the site on 7 July 2017 for £25m. Staff will move to the site in 2021, and it will be fully operational by 2024. PHE is headed by Duncan Selbie.

Structure

It is situated in Essex on the A1169, over which the site has a footbridge.

Heads of site

See also

Related Research Articles

<span class="mw-page-title-main">Ribena</span> Blackcurrant-based drink

Ribena is a brand of blackcurrant-based soft drink, and fruit drink concentrate designed to be mixed with water. It is available in bottles, cans and multi-packs. Originally of English origin, it was produced by the pharmaceutical company GlaxoSmithKline (GSK) until 2013, when the brand was sold to Japanese beverage conglomerate Suntory.

<span class="mw-page-title-main">GSK plc</span> UK healthcare company

GSK plc is a British multinational pharmaceutical and biotechnology company with global headquarters in London. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm.

Lucozade is a British brand of soft drinks and energy drinks manufactured and marketed by the Japanese company Suntory. Created as "Glucozade" in the UK in 1927 by a Newcastle pharmacist, William Walker Hunter, it was acquired by the British pharmaceutical company Beecham's in 1938 and sold as Lucozade, an energy drink for the sick. Its advertising slogan was "Lucozade aids recovery". It was sold mostly in pharmacies up until the 1980s before it was more readily available as a sports drink in shops across the UK.

<span class="mw-page-title-main">The Frythe</span>

The Frythe is a country house set in its own grounds in rural Hertfordshire, just south of the village of Welwyn, about 30 miles north of London.

<span class="mw-page-title-main">Human Genome Sciences</span> Former American pharmaceutical company, acquired by GlaxoSmithKline.

Human Genome Sciences (HGS) was a biopharmaceutical corporation founded in 1992 by Craig Venter, Alan Walton and Wally Steinberg. It uses the human DNA sequence to develop protein and antibody drugs. It had drugs under development to treat such diseases as hepatitis C, systemic lupus erythmatosis, anthrax, and cancer. It collaborated with other biotechnology and pharmaceutical companies for development partnerships and licensing.

<span class="mw-page-title-main">Dyclonine</span> Anesthetic

Dyclonine (Dyclocaine) is an oral anaesthetic that is the active ingredient of Sucrets, an over-the-counter throat lozenge. It is also found in some varieties of the Cepacol sore throat spray. It is a local anesthetic, used topically as the hydrochloride salt.

Recherche et Industrie Thérapeutiques (R.I.T.) was founded in Genval, Belgium, as a penicillin factory in 1945 by Dr Pieter De Somer, who later became the founder of the Rega Institute for Medical Research and rector of the Katholieke Universiteit Leuven. The industrialist Jean Lannoye provided the funding for the company. The company started its vaccine research and production in the 1950s. The present CEO of the company is Roger Connor.

<span class="mw-page-title-main">Beecham Group</span> Former British pharmaceutical company (1859–1989)

The Beecham Group plc was a British pharmaceutical company. It was once a constituent of the FTSE 100 Index. Founded by Thomas Beecham who opened the first factory in St Helens, Lancashire in 1859, Beecham focused on marketing the business by advertising in newspapers and using a network of wholesale agents in northern England and in London, rapidly building up the business. In August 1859 he created the slogan for Beecham's Pills: "Worth a guinea a box", considered to be the world's first advertising slogan, which helped the business become a global brand.

<span class="mw-page-title-main">Smith, Kline & French</span> First Predecessor company of GlaxoSmithKline

Smith, Kline & French (SKF) was an American pharmaceutical company.

<span class="mw-page-title-main">Andrew Witty</span> British business executive (born 1964)

Sir Andrew Philip Witty is a British business executive, who is the current chief executive officer (CEO) of UnitedHealth Group. He was also the CEO of GlaxoSmithKline between 2008 and 2017. He formerly held the role of chancellor of the University of Nottingham.

<span class="mw-page-title-main">GW501516</span> PPAR β/δ receptor agonist compound

GW501516 is a PPARδ receptor agonist that was invented in a collaboration between Ligand Pharmaceuticals and GlaxoSmithKline in the 1990s. It entered into clinical development as a drug candidate for metabolic and cardiovascular diseases, but was abandoned in 2007 because animal testing showed that the drug caused cancer to develop rapidly in several organs.

The pharmaceutical industry in the United Kingdom directly employs around 73,000 people and in 2007 contributed £8.4 billion to the UK's GDP and invested a total of £3.9 billion in research and development. In 2007 exports of pharmaceutical products from the UK totalled £14.6 billion, creating a trade surplus in pharmaceutical products of £4.3 billion.

Christopher v. SmithKline Beecham Corp., 567 U.S. 142 (2012), is a US labor law case of the United States Supreme Court. It held that pharmaceutical sales representatives were not eligible for overtime pay. The court ruled in a majority opinion written by Justice Samuel Alito that sales representatives were classified as "outside salesmen" who are exempt from the Department of Labor's regulations regarding overtime pay.

Ann Jacqueline Hunter CBE FMedSci FBPharmacolS FRSB is a British scientist who is a board director of BenevolentAI. Hunter is also a visiting professor at St George's Hospital Medical School and Imperial College. She is Chair of the Trustees of the Sainsbury Laboratories at Norwich, chair of the board of the Stevenage Bioscience Catalyst and chair of the board of Brainomix. She was previously CEO of the Biotechnology and Biological Sciences Research Council.

<span class="mw-page-title-main">Wellcome Research Laboratories</span>

Wellcome Research Laboratories was a site in Beckenham, south-east London, that was a main research centre for pharmaceuticals. Until 1965, this laboratory site was situated in Kent.

<span class="mw-page-title-main">Study 329</span> Scientific article

Study 329 was a clinical trial which was conducted in North America from 1994 to 1998 to study the efficacy of paroxetine, an SSRI anti-depressant, in treating 12- to 18-year-olds diagnosed with major depressive disorder. Led by Martin Keller, then professor of psychiatry at Brown University, and funded by the British pharmaceutical company SmithKline Beecham—known since 2000 as GlaxoSmithKline (GSK)—the study compared paroxetine with imipramine, a tricyclic antidepressant, and placebo. SmithKline Beecham had released paroxetine in 1991, marketing it as Paxil in North America and Seroxat in the UK. The drug attracted sales of $11.7 billion in the United States alone from 1997 to 2006, including $2.12 billion in 2002, the year before it lost its patent.

Jean-Pierre Garnier is a French businessman, and a former chief executive of GlaxoSmithKline.

<span class="mw-page-title-main">Old Powder Mills</span> Pharmaceutical Research Centre in Kent

The Old Powder Mills was a former research centre of GSK in Kent.

<span class="mw-page-title-main">Emma Walmsley</span> British businesswoman

Dame Emma Natasha Walmsley is the chief executive officer (CEO) of GlaxoSmithKline. She succeeded Sir Andrew Witty, who retired in March 2017. Before GSK, she worked for L'Oréal for 17 years, and was a non-executive director of Diageo until September 2016. She grew up in Barrow-in-Furness, Cumbria, England.

References

  1. Herts and Essex Observer Friday 15 August 1969, page 12
  2. Harlow Star Thursday 17 November 1988, page 3
  3. Times Tuesday November 7 1961, page 21
  4. Harlow Star Thursday 17 June 1993, page 12
  5. Harlow Star Thursday 21 July 1994, page 3
  6. Harlow Star Thursday 23 March 1995, page 1
  7. Harlow Star Thursday 28 September 1995, page 9
  8. Harlow Star Thursday 29 September 1994, page 5
  9. Harlow Star Thursday 3 August 1995, page 5
  10. Harlow Star Thursday 8 May 1997, page 4
  11. Harlow Star Thursday 1 May 1997, page 3
  12. GSK history
  13. New Scientist October 1988
  14. Times, 3 February 2000, page 24
  15. Times Thursday August 3 2000, page 81
  16. "Antyukh loses London 2012 Olympics individual medal after AIU ruling". www.insidethegames.biz. 24 October 2022. Retrieved 3 November 2023.